The International Court of Justice has released the detailed schedule for oral arguments in its advisory opinion on the Obligations of States in respect of Climate Change ...

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in ...

Students interested in an oral presentation submitted a video of no more than 3 minutes describing their project. These videos were available for public viewing and voting from March 14, 2024 to the ...

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

today announced that the company will present an oral presentation with results of a 52-week Phase 2 study in Mild-to-Moderate Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease ...

Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV ... a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

The 2023-2024 FCCLA Fashion Design students from Rockwall ISD's Dr. Gene Burton College and Career Academy placed in the Top 10 in the nation at the FCCLA National Leadership Conference held in ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsMichael Castagna - CEOChris Prentiss ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

Discover the groundbreaking innovations showcased at CHASCON-2024, featuring a state-of-the-art 5G drone for defense and agriculture and diverse scientific sessions spanning various fields. Join ...